Biomica News
21 articles
Biomica Presents Positive Clinical Data Update from Ongoing Phase 1 Trial of Microbiome-Based Therapeutic, BMC128, for Refractory RCC, NSCLC & Melanoma
Biomica to Present at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting
Biomica Successfully Completes Phase I Trial Enrollment for Microbiome-Based Immuno-Oncology Drug
Biomica Opens Second Site to Advance Its Immuno-Oncology Drug Trials at Davidoff Center
Biomica Ltd., a subsidiary of Evogene Ltd., has announced the opening of a second site at The Davidoff Cancer Center for its ongoing Phase I clinical trial of its immuno-oncology drug candidate, BMC128. The trial aims to assess the safety and tolerability of BMC128 in combination with Bristol Myers Squibbs Opdivo®, for the treatment of refractory patients with non-small cell lung cancer, melanoma, or renal cell carcinoma. The new site represents another milestone in Biomicas commitment to advancing clinical research in immuno-oncology.
PartnersExpand
Biomica Announces Interim Positive Results from Pre-Clinical Studies in its Irritable Bowel Syndrome (IBS) Program
Biomica Ltd., a subsidiary of Evogene Ltd., has reported positive interim results from pre-clinical studies of its live bacterial consortia, BMC426 and BMC427, for the treatment of Irritable Bowel Syndrome (IBS). The studies were conducted in collaboration with the lab of Prof. Kara Gross Margolis at the New York University Pain Research Center. The results showed that treatment with BMC426 and BMC427 effectively reduced visceral pain, a major symptom of IBS. The company plans to further explore these findings and develop its IBS therapeutics program.
PartnersExpand
Biomica Announces Closing of $20 Million Financing Round led by Shanghai Healthcare Capital
Biomica Ltd., a clinical-stage biopharmaceutical company, has closed a financing round of $20 million. The round was led by a $10 million investment from Shanghai Healthcare Capital (SHC), a Chinese private equity fund, and another $10 million from Evogene Ltd., Biomicas parent company. The investment will enable Biomica to continue developing its pipeline of microbiome-based therapeutics. The company plans to use the proceeds to complete its current BMC128 phase 1 immuno-oncology study and advance to phase 2 clinical trial, as well as other programs.
Investment
Biomica Raises $20M to Advance its Pipeline of Microbiome-based Therapeutics
Biomica, a clinical-stage biopharmaceutical company and subsidiary of Evogene Ltd, has raised $20M in a funding round led by Shanghai Healthcare Capital (SHC). The funding will be used to further develop Biomicas pipeline of microbiome-based therapeutics. Specifically, the company plans to complete its current BMC128 phase 1 immuno-oncology study and advance to phase 2 clinical trial, scale up and complete GMP production of BMC333 in preparation for a phase 1 clinical trial for the treatment of inflammatory bowel disease (IBD), and advance additional programs.
InvestmentExpand
Biomica CEO to Participate in an Industry Panel Discussion at Microbiome Connect USA 2022 Summit - Evogene (NASDAQ:EVGN)
Biomica Ltd., a biopharmaceutical company developing microbiome-based therapeutics, announced its participation in an industry panel discussion at the 7th Annual Microbiome Connect USA 2022 Summit. The conference is dedicated to showcasing drug development platforms applying microbes and microbial-derived components to prevent or treat human diseases. Dr. Elran Haber, CEO of Biomica, will be part of the panel discussion titled, Market Dynamics and Investment Landscape. Biomica is a subsidiary of Evogene Ltd.
Investment
Biomica Announces Successful Enrollment of First Patient in its Phase I Study of Microbiome-Based Immuno-Oncology Drug
Biomica Ltd., a subsidiary of Evogene Ltd., has announced the successful enrollment of the first patient in its Proof-of-Concept (POC) Phase I clinical trial. The trial is designed to evaluate the safety and tolerability of Biomicas microbiome-based immuno-oncology drug candidate, BMC128, in combination with immune checkpoint inhibitor (ICI) immunotherapy in patients with either non-small cell lung cancer, melanoma or renal cell carcinoma. Bristol Myers Squibbs Opdivo® is the immune checkpoint inhibitor in the trial. The trial will take place at Rambam Health Care Campus in Israel throughout 2022.
Customers
Biomica to Present at the 7th Microbiome Movement Drug Development Summit
Biomica Ltd., a biopharmaceutical company specializing in microbiome-based therapeutics, will be participating in the 7th Microbiome Movement Drug Development Summit in Boston from June 21-24, 2022. The companys CEO, Dr. Elran Haber, will be part of the opening panel and will also be available for one-on-one meetings. The summit is a significant event for microbiome drug developers, providing opportunities for collaboration and partnership establishment.
Partners
Biomica Announces Agreement with Sheba Medical Center for Joint Microbiome Clinical Research | BioSpace
Biomica Ltd., a biopharmaceutical company, has announced a collaboration with Sheba Medical Center in Tel Aviv, Israel, to conduct deep sequencing and high-resolution microbiome analysis of samples from patients with inflammatory bowel disease (IBD). The research aims to identify potential profiles, biomarkers, and therapeutic entities to gain a deeper understanding of the human microbiome in IBD patients. The findings from this study are expected to expand Biomicas expertise in this field and further its ability to develop new therapeutics for IBD. Biomica is a subsidiary of Evogene Ltd.
Partners
Biomica Announces Clearance for First-in-Human Phase I Study of BMC-128 in Combination with Bristol Myers Squibb's Anti-PD-1 Opdivo®
Biomica Ltd, a subsidiary of Evogene Ltd., has received clearance from the Israeli Ministry of Health to proceed with its Phase I clinical trial of drug candidate BMC-128 in patients with Non-Small Cell Lung Cancer, Melanoma or Renal Cell Carcinoma. The company has also entered into a supply agreement with Bristol Myers Squibb for the use of their Opdivo therapy in combination with BMC-128 in multiple cancer indications. The trial is expected to take place at Rambam Health Care Campus.
PartnersInvestment
Biomica &Rambam Health Care Campus Sign Agreement for Clinical Trial of Biomica's Microbiome-Based Immuno-Oncology Drug
Biomica Ltd., a subsidiary of Evogene Ltd., and Rambam Health Care Campus have announced the signing of a clinical trial agreement for a first in-human proof-of-concept study for BMC128, Biomicas drug candidate. The study aims to evaluate the safety and tolerability of BMC128 in combination with immune checkpoint inhibitor immunotherapy in patients with Non-small Cell Lung Cancer, Melanoma or Renal Cell Carcinoma. The initiation of this study is pending approval by the Israeli Ministry of Health. Biomicas immuno-oncology program is based on the premise that the gut microbiome affects the efficacy of cancer immunotherapy.
Partners
Biomica Enters New Agreement with Biose Industrie for Scale-up and GMP Production of Drug Candidates BMC121 & BMC127 for its Immuno-Oncology Program
Biomica, a biopharmaceutical company and subsidiary of Evogene Ltd., has entered a service agreement with Biose Industrie, a France-based CDMO, for the scale-up production of its drug candidates, BMC121 & BMC127. The agreement will accelerate Biomicas Immuno-Oncology program, which is set to enter the clinic in 2021 for proof of concept studies. The drug candidates were recently evaluated in pre-clinical studies in a mouse cancer model, showing positive effects when used in combination with checkpoint inhibitor therapy.
PartnersExpand
Biomica Reports Positive Preliminary Results in Animal Studies in Its Immuno-oncology Program
Biomica, a subsidiary of Evogene Ltd., has announced positive preliminary results from animal studies in its immuno-oncology program. The studies tested the anti-tumor activity in mice following treatment with Biomicas bacterial consortia BMC121 & BMC127. The results showed improved anti-tumor activity compared to checkpoint inhibitor therapy alone. The bacterial consortia were identified and designed based on data obtained from cancer patients who displayed varying degrees of response to immune-checkpoint inhibitors therapy. The results of these studies are the first demonstration that treatment with BMC121 & BMC127 may increase the efficacy of immune checkpoint inhibitors therapy and improve anti-tumor activity.
Investment
Evogene teams with Weizmann Nobel laureate on microbiomes
Evogenes biopharmaceutical unit, Biomica, is partnering with the Weizmann Institute of Science to develop a treatment against antibiotic-resistant strains of Staphylococcus aureus. The treatment will use the discoveries of Nobel laureate Prof. Ada Yonath in high-resolution crystal structure. Biomica will use this technology to design specific molecules that selectively target and inhibit the large ribosomal subunit of the pathogenic Staphylococcus aureus. The collaboration aims to address the global issue of antibiotic resistance.
Partners
Biomica To Collaborate with Weizmann Institute of Science to Develop A Selective Treatment Against Antibiotic Resistant Bacteria - Evogene
Biomica, a biopharmaceutical company and subsidiary of Evogene Ltd., has announced a collaboration with the Weizmann Institute of Science to develop a treatment against antibiotic resistant strains of Staphylococcus aureus infection. The company has in-licensed IP and knowhow from Nobel Prize laureate Prof. Ada Yonath, who will advise Biomica on the program. The treatment aims to target a specific microbe while maintaining the microbiome of the patients’ gut. Biomica aims to use the in-licensed IP and knowhow to design specific molecules that selectively target and inhibit the large ribosomal subunit of the pathogenic Staphylococcus aureus.
Partners
Biomica Announces Advancement to Pre-Clinical Studies in its Inflammatory Bowel Disease Program - Evogene
Biomica, a biopharmaceutical company and subsidiary of Evogene Ltd., has announced the initiation of pre-clinical studies for BMC321 & BMC322, two microbiome-based therapeutics aimed at reducing inflammation for the treatment of Inflammatory Bowel Disease (IBD). This is the second program Biomica has advanced to pre-clinical studies. The companys IBD drug development program uses a unique scientific approach targeting multiple microbial-related mechanisms that underlay the intestinal inflammation of IBD. The company also announced the addition of Prof. David T. Rubin, a renowned gastroenterologist, as a scientific and medical advisor.
Management ChangesExpand
Biomica Announces the Addition of Internationally Renowned Experts in the Fields of Gastroenterology and the Human Microbiome to its Scientific Advisory Board
Biomica, a subsidiary of Evogene Ltd., has announced the addition of internationally renowned experts to its scientific advisory board. The new members will join Prof. Yehuda Ringel, Biomica co-founder and CSO, to support the company’s upcoming steps towards its clinical development. The experts joining Biomica’s scientific advisory board include Prof. Willem M De Vos, Prof. R. Balfour Sartor, Prof. James Versalovic, and Dr. Ravid Straussman. Biomica is an emerging biopharmaceutical company developing innovative microbiome-based therapeutics.
Management ChangesExpand
Biomica, Evogene's Newly Established Subsidiary, Announces Therapeutic Areas of Focus
Biomica, a subsidiary of Evogene Ltd., is focusing on the development of therapies for antibiotic resistant bacteria, Immuno-Oncology and GI related disorders. The company is using Evogenes Computational Predictive Biology (CPB) platform to develop these therapies. The human gut microbiome, which is the collection of trillions of micro-organisms that exist in the digestive tract, plays key roles in various functions in human health. Biomica is leveraging a tailored CPB platform tool-set to identify and characterize disease related changes in the human microbiome, and to develop novel therapeutics based on these understandings.
InvestmentExpand
Evogene unit Biomica designs molecules to analyze bacteria
Israeli start-up Biomica is using big data to analyse the interface between the bacterial environment of human beings and the human body. The company, a spin-off from Evogene, is developing a product that can destroy a specific bacterium, which could be used in the treatment of cancer, digestive tract diseases and infectious diseases. The venture is still at the computational stage, with no trials having been conducted so far. Biomica was born as a cooperative effort between Evogene and microbiome guru Prof. Yehuda Ringel, director of gastroenterology at Meir Medical Center. Evogene holds 90% of Biomica.
InvestmentPartners
